Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Next Previous
X
Search
Trial Profile

An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms DASISION
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 17 Jun 2021 Results of post-hoc analysis assessing the effect of comorbidities on response outcomes with dasatinib vs imatinib, presented at the 26th Congress of the European Haematology Association.
    • 08 Dec 2020 Results of exploratory post hoc analysis of DASISION at 5 years follow-up, investigating the effect of comorbidities on response outcomes with dasatinib vs imatinib presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 06 Nov 2019 Results of an exploratory post hoc analysis from this study assessing the association of high BMI with treatment responses with 1L TKIs, were released in the 61st Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top